

Connecticut HB 6669 Disclosure

XOLREMDI® (Mavorixafor)

X4 Pharmaceuticals, Inc. (X4) provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects X4 Wholesale Acquisition Costs (“WAC”) for the X4 product: XOLREMDI®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for XOLREMDI®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
XOLREMDI® (Mavorixafor)	83296-0100-12	Capsule 100 MG	\$43,656.00
XOLREMDI® (Mavorixafor)	83296-0100-60	Capsule 100 MG	\$21,828.00
XOLREMDI® (Mavorixafor)	83296-0100-90	Capsule 100 MG	\$32,742.00

Generic versions of XOLREMDI are not currently available.

XOLREMDI® is a registered trademark of X4 Pharmaceuticals, Inc.

Copyright© 2025 X4 All rights reserved.

3/27/2025